• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲抗中性粒细胞胞浆抗体相关性血管炎注册研究中的数据质量和患者特征:通过联合查询进行数据检索。

Data quality and patient characteristics in European ANCA-associated vasculitis registries: data retrieval by federated querying.

机构信息

Clinical Sciences, Rheumatology, Lund University, Lund, Sweden

School of Infection and Immunity, University of Glasgow, Glasgow, UK.

出版信息

Ann Rheum Dis. 2024 Jan 2;83(1):112-120. doi: 10.1136/ard-2023-224571.

DOI:10.1136/ard-2023-224571
PMID:37907255
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10804071/
Abstract

OBJECTIVES

This study aims to describe the data structure and harmonisation process, explore data quality and define characteristics, treatment, and outcomes of patients across six federated antineutrophil cytoplasmic antibody-associated vasculitis (AAV) registries.

METHODS

Through creation of the vasculitis-specific Findable, Accessible, Interoperable, Reusable, VASCulitis ontology, we harmonised the registries and enabled semantic interoperability. We assessed data quality across the domains of uniqueness, consistency, completeness and correctness. Aggregated data were retrieved using the semantic query language SPARQL Protocol and Resource Description Framework Query Language (SPARQL) and outcome rates were assessed through random effects meta-analysis.

RESULTS

A total of 5282 cases of AAV were identified. Uniqueness and data-type consistency were 100% across all assessed variables. Completeness and correctness varied from 49%-100% to 60%-100%, respectively. There were 2754 (52.1%) cases classified as granulomatosis with polyangiitis (GPA), 1580 (29.9%) as microscopic polyangiitis and 937 (17.7%) as eosinophilic GPA. The pattern of organ involvement included: lung in 3281 (65.1%), ear-nose-throat in 2860 (56.7%) and kidney in 2534 (50.2%). Intravenous cyclophosphamide was used as remission induction therapy in 982 (50.7%), rituximab in 505 (17.7%) and pulsed intravenous glucocorticoid use was highly variable (11%-91%). Overall mortality and incidence rates of end-stage kidney disease were 28.8 (95% CI 19.7 to 42.2) and 24.8 (95% CI 19.7 to 31.1) per 1000 patient-years, respectively.

CONCLUSIONS

In the largest reported AAV cohort-study, we federated patient registries using semantic web technologies and highlighted concerns about data quality. The comparison of patient characteristics, treatment and outcomes was hampered by heterogeneous recruitment settings.

摘要

目的

本研究旨在描述数据结构和协调过程,探索数据质量,并定义六个联邦抗中性粒细胞胞浆抗体相关性血管炎 (AAV) 登记处患者的特征、治疗和结局。

方法

通过创建专门针对血管炎的可查找、可访问、互操作、可重复使用的 VASCulitis 本体,我们协调了登记处并实现了语义互操作性。我们评估了各个域的独特性、一致性、完整性和正确性。使用语义查询语言 SPARQL Protocol and Resource Description Framework Query Language (SPARQL) 检索聚合数据,并通过随机效应荟萃分析评估结局发生率。

结果

共确定了 5282 例 AAV 病例。所有评估变量的独特性和数据类型一致性均为 100%。完整性和正确性分别为 49%-100%至 60%-100%。2754 例(52.1%)被归类为肉芽肿性多血管炎(GPA),1580 例(29.9%)为显微镜下多血管炎,937 例(17.7%)为嗜酸性粒细胞性 GPA。器官受累的模式包括:3281 例(65.1%)肺部受累,2860 例(56.7%)耳部-鼻部-咽喉受累,2534 例(50.2%)肾脏受累。982 例(50.7%)患者使用静脉注射环磷酰胺作为缓解诱导治疗,505 例(17.7%)患者使用利妥昔单抗,静脉注射糖皮质激素的使用情况差异很大(11%-91%)。总体死亡率和终末期肾病的发生率分别为每 1000 患者年 28.8(95%CI 19.7 至 42.2)和 24.8(95%CI 19.7 至 31.1)。

结论

在报告的最大 AAV 队列研究中,我们使用语义网技术联合了患者登记处,并强调了对数据质量的关注。由于招募环境的异质性,患者特征、治疗和结局的比较受到阻碍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da92/10804071/f19d9a9cacc1/ard-2023-224571f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da92/10804071/38331e36494e/ard-2023-224571f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da92/10804071/f84d19019012/ard-2023-224571f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da92/10804071/aacd41d91707/ard-2023-224571f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da92/10804071/f19d9a9cacc1/ard-2023-224571f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da92/10804071/38331e36494e/ard-2023-224571f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da92/10804071/f84d19019012/ard-2023-224571f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da92/10804071/aacd41d91707/ard-2023-224571f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da92/10804071/f19d9a9cacc1/ard-2023-224571f04.jpg

相似文献

1
Data quality and patient characteristics in European ANCA-associated vasculitis registries: data retrieval by federated querying.欧洲抗中性粒细胞胞浆抗体相关性血管炎注册研究中的数据质量和患者特征:通过联合查询进行数据检索。
Ann Rheum Dis. 2024 Jan 2;83(1):112-120. doi: 10.1136/ard-2023-224571.
2
Childhood-Onset ANCA- Associated Vasculitis: single center experience from Central California.儿童发病的抗中性粒细胞胞浆抗体相关性血管炎:来自加利福尼亚中部的单中心经验。
Pediatr Rheumatol Online J. 2023 Jul 3;21(1):66. doi: 10.1186/s12969-023-00853-4.
3
The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 266 AAV patients.德语国家联合血管炎登记处(GeVas):266 例 AA V 患者的亚组分析。
Clin Exp Rheumatol. 2024 Apr;42(4):852-858. doi: 10.55563/clinexprheumatol/suxkyq. Epub 2024 Apr 12.
4
Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort.基于数据驱动的抗中性粒细胞胞质抗体相关性血管炎亚分类:国际合作队列的基于模型的聚类分析。
Lancet Rheumatol. 2024 Nov;6(11):e762-e770. doi: 10.1016/S2665-9913(24)00187-5. Epub 2024 Aug 22.
5
Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway.挪威北部抗中性粒细胞胞浆抗体相关性血管炎的发病率和患病率不断增加。
Rheumatology (Oxford). 2020 Sep 1;59(9):2316-2324. doi: 10.1093/rheumatology/kez597.
6
Disease and treatment-related morbidity in young and elderly patients with granulomatosis with polyangiitis and microscopic polyangiitis.年轻和老年肉芽肿性多血管炎和显微镜下多血管炎患者的疾病和治疗相关发病率。
Semin Arthritis Rheum. 2020 Dec;50(6):1441-1448. doi: 10.1016/j.semarthrit.2020.02.008. Epub 2020 Feb 24.
7
Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.基于抗中性粒细胞胞浆抗体(ANCA)类型的ANCA相关性血管炎治疗的临床结果。
Ann Rheum Dis. 2016 Jun;75(6):1166-9. doi: 10.1136/annrheumdis-2015-208073. Epub 2015 Nov 30.
8
Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.甲氨蝶呤与环磷酰胺用于抗中性粒细胞胞浆抗体相关性血管炎缓解期维持治疗的随机试验
PLoS One. 2017 Oct 10;12(10):e0185880. doi: 10.1371/journal.pone.0185880. eCollection 2017.
9
Respiratory involvement in antineutrophil cytoplasmic antibody-associated vasculitides: a retrospective study based on POLVAS registry.抗中性粒细胞胞浆抗体相关性血管炎的肺部受累:基于 POLVAS 登记研究的回顾性研究。
Clin Exp Rheumatol. 2022 May;40(4):720-726. doi: 10.55563/clinexprheumatol/tvtyen. Epub 2022 Apr 27.
10
Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis.抗中性粒细胞胞浆抗体相关性血管炎中心脏受累的患病率及预后相关性:嗜酸性肉芽肿性多血管炎和肉芽肿性多血管炎
Int J Cardiol. 2015 Nov 15;199:170-9. doi: 10.1016/j.ijcard.2015.06.087. Epub 2015 Jul 15.

引用本文的文献

1
Making the Case for an International Childhood Cancer Data Partnership.推动建立国际儿童癌症数据伙伴关系的理由。
J Natl Cancer Inst. 2025 Jan 12. doi: 10.1093/jnci/djaf003.
2
Trends in health care of patients with vasculitides, including giant cell arteritis, Takayasu arteritis, ANCA-associated vasculitis and Behçet's disease: cross-sectional data of the German National Database 2007-2021.血管炎患者(包括巨细胞动脉炎、Takayasu 动脉炎、ANCA 相关性血管炎和 Behçet 病)的医疗保健趋势:2007 年至 2021 年德国国家数据库的横断面数据。
Rheumatol Int. 2024 Mar;44(3):497-507. doi: 10.1007/s00296-023-05508-x. Epub 2024 Jan 5.

本文引用的文献

1
ANCA-associated vasculitis in Ireland: a multi-centre national cohort study.爱尔兰的抗中性粒细胞胞浆抗体相关性血管炎:一项多中心全国队列研究。
HRB Open Res. 2022 Dec 1;5:80. doi: 10.12688/hrbopenres.13651.1. eCollection 2022.
2
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.EULAR 推荐的抗中性粒细胞胞浆抗体相关性血管炎治疗:2022 年更新。
Ann Rheum Dis. 2024 Jan 2;83(1):30-47. doi: 10.1136/ard-2022-223764.
3
Stable incidence but increase in prevalence of ANCA-associated vasculitis in southern Sweden: a 23-year study.
瑞典南部抗中性粒细胞胞浆抗体相关性血管炎发病率稳定但患病率增加:一项 23 年的研究。
RMD Open. 2023 Mar;9(1). doi: 10.1136/rmdopen-2022-002949.
4
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis.抗中性粒细胞胞质抗体相关性血管炎患者的长期预后和生存的预测因素。
Nephrol Dial Transplant. 2023 Jun 30;38(7):1655-1665. doi: 10.1093/ndt/gfac320.
5
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report.互联互通之声;欧洲血管炎学会2022年报告
Kidney Int Rep. 2022 May 25;7(8):1745-1757. doi: 10.1016/j.ekir.2022.05.018. eCollection 2022 Aug.
6
FAIRVASC: A semantic web approach to rare disease registry integration.FAIRVASC:一种语义网方法,用于整合罕见病登记处。
Comput Biol Med. 2022 Jun;145:105313. doi: 10.1016/j.compbiomed.2022.105313. Epub 2022 Mar 1.
7
Quality of Hospital Electronic Health Record (EHR) Data Based on the International Consortium for Health Outcomes Measurement (ICHOM) in Heart Failure: Pilot Data Quality Assessment Study.基于国际健康结局测量协会(ICHOM)心力衰竭标准的医院电子健康记录(EHR)数据质量:试点数据质量评估研究
JMIR Med Inform. 2021 Aug 4;9(8):e27842. doi: 10.2196/27842.
8
The Joint Vasculitis Registry in German-speaking countries (GeVas) - a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis.德语国家联合血管炎注册研究(GeVas)——一项用于血管炎长期结局随访的前瞻性多中心注册研究。
BMC Rheumatol. 2021 Jul 31;5(1):40. doi: 10.1186/s41927-021-00206-2.
9
The future of digital health with federated learning.联合学习助力数字健康的未来。
NPJ Digit Med. 2020 Sep 14;3:119. doi: 10.1038/s41746-020-00323-1. eCollection 2020.
10
Interoperability of population-based patient registries.基于人群的患者登记系统的互操作性。
J Biomed Inform X. 2020 Sep;6:100074. doi: 10.1016/j.yjbinx.2020.100074. Epub 2020 Jun 13.